Company Filing History:
4 out of 11 
2 out of 1,327 
1 out of 18 Years Active: 2016-2022
Title: The Innovations of Peter Johannes Goedings
Introduction
Peter Johannes Goedings is a notable inventor based in Nijmegen, Netherlands. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of antibody-drug conjugates (ADCs). With a total of five patents to his name, Goedings has focused on innovative treatments for various types of cancer.
Latest Patents
One of his latest patents involves duocarmycin-containing ADCs that demonstrate improved in vivo antitumor activity. This invention is aimed at treating human solid tumors and hematological malignancies that express HER2, including breast cancer, gastric cancer, and several others. Specifically, it addresses the treatment of triple-negative breast cancer (TNBC) and solid tumors with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. This advancement holds promise for enhancing therapeutic options for patients suffering from these challenging cancers.
Career Highlights
Throughout his career, Goedings has worked with prominent organizations such as Synthon Biopharmaceuticals B.V. and Yale University. His experience in these institutions has allowed him to collaborate on groundbreaking research and development projects in the biopharmaceutical sector.
Collaborations
Some of his notable coworkers include Willem Dokter and Gijsbertus Franciscus Maria Verheijden. Their collective expertise has contributed to the success of various projects and innovations in the field.
Conclusion
Peter Johannes Goedings exemplifies the spirit of innovation in the biopharmaceutical industry. His work on duocarmycin-containing ADCs represents a significant step forward in cancer treatment, showcasing his commitment to improving patient outcomes.